SCHEMBL4850654

SCHEMBL4850654

COc1cc(C=O)ccc1OCc1nc(-c2cccc(CC(=O)O)c2)oc1C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDR P35968 1/20 0.46
KDM4E B2RXH2 2/20 0.45
FFAR1 O14842 1/20 0.45
KMT2A Q03164 1/20 0.44
VDR P11473 1/20 0.44
PPARD Q03181 1/20 0.44
MAPT P10636 2/20 0.44
CYP2C9 P11712 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PPARG P37231 4/20 0.43
PPARA Q07869 4/20 0.43
KCNH2 Q12809 1/20 0.43
APP P05067 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4845465 0.90 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EFFAR1KMT2A
SCHEMBL4845464 0.87 KDR (0.57) ALDH1A1SMN1; SMN2KDRKDM4EFFAR1
SCHEMBL6157314 0.87 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDRKDM4EFFAR1
SCHEMBL4846412 0.86 FFAR1 (0.48) ALDH1A1SMN1; SMN2KDRKDM4EFFAR1
SCHEMBL4843985 0.85 FFAR1 (0.59) ALDH1A1SMN1; SMN2KDRKDM4EFFAR1
SCHEMBL4855222 0.85 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KDM4EVDRPPARD
SCHEMBL4029430 0.83 MAPT (0.50) ALDH1A1SMN1; SMN2KDRKDM4EFFAR1
SCHEMBL4845854 0.82 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDRFFAR1KMT2A
SCHEMBL4852739 0.81 L3MBTL1 (0.50) ALDH1A1SMN1; SMN2KDM4EKMT2AMAPT
SCHEMBL4851743 0.81 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 ALDH1A1 821/4885SMN1; SMN2 4339/4885KDR 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.